|
|
Volumn 47, Issue 10, 2008, Pages 1320-1327
|
|
Value of targeted therapy for penile cancer;Der stellenwert der tageted-therapie beim peniskarzinom
|
|
Author keywords
Chemotherapy; Metastatic disease; Molecular pathogenesis; Squamous cell carcinoma; Targeted therapy
|
|
Indexed keywords
ALPHA INTERFERON;
ANTHRACYCLINE;
BEVACIZUMAB;
BLEOMYCIN;
CARBOPLATIN;
CETUXIMAB;
CISPLATIN;
CYCLIN D1;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITOR;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERLOTINIB;
GEFITINIB;
IFOSFAMIDE;
METHOTREXATE;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY KI 67;
PACLITAXEL;
PROSTAGLANDIN E2;
PROTEIN BAX;
PROTEIN BCL 2;
PROTEIN MDM2;
PROTEIN P16;
PROTEIN P22;
PROTEIN P53;
PROTEIN TYROSINE KINASE INHIBITOR;
TRASTUZUMAB;
UVOMORULIN;
VINCRISTINE;
ANTIANGIOGENIC ACTIVITY;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER CONTROL;
CANCER IMMUNOTHERAPY;
CANCER INCIDENCE;
CANCER REGRESSION;
CANCER SURVIVAL;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
DRUG TARGETING;
HUMAN;
LUNG CARCINOMA;
LYMPH NODE METASTASIS;
METASTASIS;
PATHOGENESIS;
PENIS CARCINOMA;
PROGNOSIS;
PROTEIN EXPRESSION;
PROTEIN TARGETING;
REVIEW;
SQUAMOUS CELL CARCINOMA;
TUMOR SUPPRESSOR GENE;
WART VIRUS;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC AGENTS;
CHEMOTHERAPY, ADJUVANT;
CYCLOOXYGENASE 2 INHIBITORS;
DRUG DELIVERY SYSTEMS;
HUMANS;
MALE;
NEOADJUVANT THERAPY;
NEOPLASM STAGING;
PENILE NEOPLASMS;
PROTEIN-TYROSINE KINASES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
RECEPTOR, ERBB-2;
SURVIVAL RATE;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 53249156118
PISSN: 03402592
EISSN: None
Source Type: Journal
DOI: 10.1007/s00120-008-1749-7 Document Type: Review |
|
Times cited : (6)
|
|
References (54)
|
